OCEAN: A Phase 3, Randomized, Global Study of Melflufen and Dexamethasone Versus Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Refractory to Lenalidomide

被引：0

作者：

Sonneveld, Pieter ^{[1
]}

Schjesvold, Fredrik ^{[2
,3
]}

Robak, Pawel ^{[4
]}

Rossjey, Viktor ^{[5
]}

Pour, Ludk ^{[6
]}

Minarik, Jiri ^{[7
]}

Delimpasi, Sosana ^{[8
]}

Legic, Wojciech ^{[9
]}

Salogub, Galina ^{[10
]}

Harmenberg, Johan ^{[11
]}

Byrne, Catriona ^{[11
]}

Nordstrom, Eva ^{[11
]}

Richardson, Paul G. ^{[12
]}

机构：

[1] Erasmus MC, Rotterdam, Netherlands

[2] Oslo Univ Hosp, Oslo Myeloma Ctr, Oslo, Norway

[3] Univ Oslo, KG Jebsen Ctr B Cell Malignancies, Oslo, Norway

[4] Med Univ Lodz, Nicolaus Copernicus Prov Multispecialty Oncol & T, Lodz, Poland

[5] VD Seredavin Samara Reg Clin Hosp, Samara, Russia

[6] Univ Hosp Brno, Brno, Czech Republic

[7] Univ Hosp Olomouc, Olomouc, Czech Republic

[8] Evangelismos Gen Hosp Athens, Athens, Greece

[9] Independent Publ Teaching Hosp 1, Lublin, Poland

[10] VA Almazov North West Fed Med Res Ctr, St Petersburg, Russia

[11] Oncopeptides AB, Stockholm, Sweden

[12] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P-036

引用

页码：S25 / S25

页数：1